FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

In April 2017, the U.S. Food and Drug Administration granted regular approval to midostaurin for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM‐AHN), or mast cell leukemia (MCL). Approval was based on resu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Kasamon, Yvette L., Ko, Chia‐Wen, Subramaniam, Sriram, Ma, Lian, Yang, Yuching, Nie, Lei, Shord, Stacy, Przepiorka, Donna, Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6292539/
https://ncbi.nlm.nih.gov/pubmed/30115735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0222
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados